Xylam Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 11 Year, 25 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 35.69%
(FY 2022)
- Profit 409.78%
(FY 2022)
- Ebitda 469.91%
(FY 2022)
- Net Worth 54.97%
(FY 2022)
- Total Assets 12.31%
(FY 2022)
About Xylam Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gyanendra Baghel, Reena Yadav, and Pradeep Kumar serve as directors at the Company.
- CIN/LLPIN
U24100MP2013PTC031846
- Company No.
031846
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Xylam Remedies Private Limited offer?
Xylam Remedies Private Limited offers a wide range of products and services, including BPO Operations and Services, BPO Services, Job Consultation Service, Recruitment Service.
Who are the key members and board of directors at Xylam Remedies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gyanendra Baghel  | Managing Director | 28-Nov-2013 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Reena Yadav | Director | 30-Nov-2019 | Current |
| Pradeep Kumar | Director | 16-Apr-2019 | Current |
Financial Performance of Xylam Remedies.
Xylam Remedies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 35.69% increase. The company also saw a substantial improvement in profitability, with a 409.78% increase in profit. The company's net worth Soared by an impressive increase of 54.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xylam Remedies?
In 2020, Xylam Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Protea Pharma Private LimitedActive 8 years 9 monthsGyanendra Baghel and Pradeep Kumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xylam Remedies?
Unlock and access historical data on people associated with Xylam Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xylam Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xylam Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
